Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Notified Bodies Must Be Involved In EU Joint HTA Discussions, Urges BSI Clinical Compliance Lead

Executive Summary

The EU Regulation on HTA will see some medtech manufacturers offered scientific advice on planned clinical investigations. According to BSI’s global head of clinical compliance, MDR/IVDR notified bodies can offer valuable expertise and must not be left out of these discussions.

You may also be interested in...

What Does The EU Regulation On HTA Mean For Medtech And When Will It Apply?

Several updates have come in recent weeks on the European Commission’s planned new Regulation on HTA, including a list of stakeholder members and updated rolling timeline. Medtech Insight explains how and when this legislation will affect the medtech sector.

Implementing The EU MDR Amendment: “Messy” And “A Lot To Figure Out On The Hoof”

The EU Medical Device Regulation amending regulation is not some kind of “bail-out or blanket extension” for manufacturers, medtech expert lawyer Erik Vollebregt warns. But it offers valuable opportunities to already-prepared manufacturers.

How Can The EU Get Clinical Evaluations For High-Risk Devices Right?

The new EU medtech regulations were developed as a reaction to unsafe products reaching patients; yet implementing new rules on clinical evidence has been anything but smooth. An expert from the BioMed Alliance tells Medtech Insight how this challenge can be addressed.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts